v3.26.1
Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenues $ 47,445 $ 50,746
Cost of products sold 37,335 38,001
Gross profit 10,110 12,745
Operating expenses:    
Research and development 2,961 2,404
Selling, general and administrative 7,364 6,942
Total operating expenses 10,325 9,346
Operating (loss) income (215) 3,399
Other expense (income):    
Interest and financing expense 868 1,032
Miscellaneous income (420) (79)
Total other expense, net 448 953
(Loss) income before income taxes (663) 2,446
Income tax (benefit) provision (192) 567
Net (loss) income (471) 1,879
Net (loss) income attributable to non-controlling interest (20) 14
Net (loss) income attributable to Ultralife Corporation    
(Loss) income attributable to Ultralife Corporation (451) 1,865
Foreign currency translation adjustments 83 311
Comprehensive (loss) income attributable to Ultralife Corporation $ (368) $ 2,176
Net (loss) income per share attributable to Ultralife Corporation common stockholders – Basic (in dollars per share) $ (3) $ 11
Net (loss) income per share attributable to Ultralife Corporation common stockholders – Diluted (in dollars per share) $ (3) $ 11
Weighted average shares outstanding – Basic (in shares) 16,657 16,633
Potential common shares (in shares) 0 47
Weighted average shares outstanding – Diluted (in shares) 16,657 16,680